APOE Gene Therapy
Alzheimer's Disease (APOE4)
PreclinicalActive
Key Facts
About Voyager Therapeutics
Voyager Therapeutics is dedicated to developing transformative gene therapies for neurological disorders by leveraging human genetics and its proprietary TRACER™ capsid discovery platform. The company's strategy combines internal pipeline development with strategic platform collaborations to de-risk R&D and generate non-dilutive funding. Key achievements include the generation of novel, IV-administered capsids with enhanced brain tropism and a pipeline featuring multiple preclinical and IND-enabling programs for high-need conditions like Alzheimer's and ALS.
View full company profileTherapeutic Areas
Other Alzheimer's Disease (APOE4) Drugs
| Drug | Company | Phase |
|---|---|---|
| Alzheimer's Disease Program | Selonterra | Preclinical |